Brainsway (BWAY) Projected to Post Quarterly Earnings on Wednesday

Brainsway (NASDAQ:BWAY) is projected to issue its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $14.6330 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

Brainsway (NASDAQ:BWAY) last announced its earnings results on Wednesday, March 11th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. The business had revenue of $14.55 million during the quarter, compared to analysts’ expectations of $14.02 million. Brainsway had a net margin of 14.62% and a return on equity of 11.10%. On average, analysts expect Brainsway to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Brainsway Price Performance

Shares of Brainsway stock opened at $16.42 on Wednesday. The stock has a market capitalization of $657.29 million, a P/E ratio of 65.68 and a beta of 1.23. The company has a 50-day simple moving average of $14.09 and a 200 day simple moving average of $11.20. Brainsway has a 12-month low of $4.30 and a 12-month high of $16.95.

Analysts Set New Price Targets

BWAY has been the subject of a number of recent analyst reports. HC Wainwright dropped their target price on shares of Brainsway from $30.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, March 12th. Zacks Research upgraded shares of Brainsway from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 24th. Weiss Ratings upgraded shares of Brainsway from a “hold (c)” rating to a “buy (b-)” rating in a research report on Friday, April 24th. Northland Securities set a $15.00 target price on shares of Brainsway in a research report on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of Brainsway from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $15.00.

Institutional Investors Weigh In On Brainsway

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. acquired a new stake in Brainsway in the 2nd quarter valued at about $85,000. Bank of America Corp DE acquired a new stake in Brainsway in the 3rd quarter valued at about $107,000. Royal Bank of Canada increased its position in Brainsway by 1,145.9% in the 4th quarter. Royal Bank of Canada now owns 8,410 shares of the company’s stock valued at $160,000 after acquiring an additional 7,735 shares in the last quarter. Centiva Capital LP acquired a new stake in Brainsway in the 3rd quarter valued at about $181,000. Finally, NewEdge Advisors LLC increased its position in Brainsway by 61.5% in the 1st quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock valued at $188,000 after acquiring an additional 7,549 shares in the last quarter. Institutional investors and hedge funds own 30.11% of the company’s stock.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.